Showing results (961-970 of 980) with videos related to
Sort By:
Pageof 98
Current Drug Safety|February 4, 2025
Comprehensive Review of Gestational Diabetes: Pathophysiology, Pharmacological Management and the Role of Pharmaceutical CareAbdulkadir Abdu, Hossamaldeen BakreyCurrent Drug Safety|January 4, 2025
The Presence of Nitrosamines and Nitrosamine Drug-Related Substances in Pharmaceutical Products: An Overview of Regulatory Concerns, Analytical Methodologies, and Control StrategiesNeha Dhansekar, Pratiksha Rale, Yogesh GhalsasiCurrent Drug Safety|November 30, 2023
Association of Cardiovascular Events with COVID-19 Vaccines Using Vaccine Adverse Event Reporting System (VAERS): A Retrospective StudyMohd Amir, S Latha, Ruchika Sharma, et al.Current Drug Safety|February 4, 2024
Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction ReportsAtul Khurana, Harikesh Dubey, Mandeep Kumar AroraCurrent Drug Safety|January 26, 2024
A Severe Case of Isotretinoin Induced Eosinophilic Pneumonia and Pericardial Effusion, a Case ReportAnne Kampman, Laurien Keulers, Jan van der Maten, et al.Current Drug Safety|January 11, 2024
Unveiling the Latest Breakthroughs: A Comprehensive Review of the Therapeutic Activity and Safety Profile of Aloe veraAlimuddin Saifi, Alok Sharma, Anurag Chaudhary, et al.Current Drug Safety|September 20, 2024
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome with Multiple Drugs (Leflunomide and Cefuroxime): A Case ReportPooja Yadav, Gopal Krishna Rao, Padmanabh V Rataboli, et al.Current Drug Safety|August 4, 2023
Amphotericin-B-Induced Chronic Kidney Disease in a Post-COVID-19 Patient with Widespread Rhinocerebral Mucormycosis and Pneumonia: A Case ReportNishant Johri, Ambika Choudhary, Ujjawal Rawat, et al.Current Drug Safety|August 3, 2023
Enhancing the Efficiency of the Individual Case Safety Report (ICSR) Quality and Compliance through AutomationShannon Link, Adam Kammler, Ritu Gupta, et al.Current Drug Safety|August 1, 2023
Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of AdministrationRichard H WoodsPageof 98